Opendata, web and dolomites

UNPACK PD-L1 SIGNED

Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UNPACK PD-L1 project word cloud

Explore the words cloud of the UNPACK PD-L1 project. It provides you a very rough idea of what is the project "UNPACK PD-L1" about.

little    successful    melanoma    drug    herein    types    exploited    clinical    lay    rationale    plausible    small    basic    l1    reveal    gaps    membrane    subsequent    patients    modality    circulating    intend    secretion    release    bioluminescent    inhibition    surround    inhibitors    immune    ligand    pd    models    stratify    function    remove    vitro    uncover    tumorigenic    death    checkpoint    stage    harnessing    tested    levels    bottlenecks    responder    strategy    drive    reporters    inhibiting    vesicles    candidates    systemic    responders    bracket    molecular    combining    upregulation    therapeutic    mechanisms    extracellular    oncological    inhibit    anti    pro    loading    receptor    programmed    unanticipated    limited    cancer    center    mouse    express    suppress    guide    optical    clear    agents    suppression    plasma    power    block    sought    ideally    therapy    immunosuppression    druggable    broaden    treat    secrete    tumour    screen    blockade    initiated    therapies    outcome    direction    meant    mediated    cells    cell    restore    tumor    groundwork    efficacy    highlighting    clinically    evs    ev    mechanism   

Project "UNPACK PD-L1" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 175˙572 €
 EC max contribution 175˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 175˙572.00

Map

 Project objective

Harnessing the power of the immune system to treat cancer has long been a sought after goal of oncological research. Immune checkpoint inhibitors, such as anti-programmed death receptor 1 (PD-1) blockade therapies, have now taken center stage. However not all patients respond, highlighting gaps in our understanding of the mechanisms of tumour immunosuppression. Upregulation of the PD-1 ligand (PD-L1) on tumour cells initiated this therapeutic direction, yet it is becoming clear that the modality of PD-L1-mediated immune suppression is not limited to the plasma membrane. Like many tumor cells, melanoma cells secrete small extracellular vesicles (EVs) with pro-tumorigenic properties. Melanoma EVs express PD-L1 that suppress T cell function and facilitate tumour growth in pre-clinical mouse models. This systemic mechanism is clinically relevant, as circulating EV-PD-L1 levels can stratify anti-PD-1 clinical responders from non-responders. Thus inhibiting EV-PD-L1 may increase anti-PD-1 efficacy and broaden the responder bracket. One plausible strategy would be to block tumor EV secretion, yet little is known about the molecular mechanisms that drive PD-L1 loading and release. Herein, I intend to uncover the molecular mechanisms of EV PD-L1 release from melanoma cells using state-of-the-art optical and bioluminescent reporters to reveal novel druggable targets. This basic knowledge will be exploited to guide subsequent inhibition, through a drug screen for candidates that inhibit EV-PD-L1 release and restore T cell function. Ideally the outcome of this in vitro study will provide a strong rationale for combining anti-PD-1 agents with inhibitors of EV-PD-L1 secretion, to be tested in pre-clinical mouse models. If successful, melanoma EV blockade may remove the unanticipated bottlenecks that surround the efficacy of anti-PD-1 therapy. In the long term this study is meant to lay groundwork for tumor EV inhibition as a therapeutic strategy for cancer types beyond melanoma.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNPACK PD-L1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNPACK PD-L1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ReSOLeS (2019)

New Reconfigurable Spectrum Optical Fibre Laser Sources

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More